Food Safety Crackdown: Hong Kong’s FEHD launched “Dawn Net” to target illegal hawking of high-risk food, arresting 6 suspects and seizing about 260kg of items including cooked food, lunch boxes, bread, beverages and expired food. Public Health & Disease Prevention: Taiwan reported a new COVID-19 epidemic phase, with 4,766 cases in July 12–18 (up 66.5% week-on-week) and officials urging hospital visits and rapid tests for people with fever, cough or sore throat after travel. Early Heart Risk Testing: HKU researchers unveiled an AI blood test (CardiOmicScore) that may flag risk of six major cardiovascular diseases up to 15 years before symptoms. Healthcare Innovation & Pharma Deals: Ashlins Pharmaceuticals signed an exclusive license and supply agreement with Lee’s Pharm for interferon alpha-2b products outside Mainland China, Hong Kong, Macau and Taiwan, worth up to $31m. Clinical Research Update: Data on olverembatinib plus blinatumomab showed high early response rates in relapsed/refractory Ph+ CML and Ph+ B-ALL, with ongoing phase 3 work. Local Enforcement at the Border: Hong Kong Customs seized 250 illegally imported live birds at Lok Ma Chau Spur Line Control Point, arresting two passengers and warning of penalties under animal import rules. Reproductive Health Spotlight: Sow Fertility’s CEO was recognised for closing support gaps in women’s reproductive health. Tech-to-Health Trend: Ping An showcased AI products for healthcare, insurance and payments at WAIC 2026, including disease prediction and cancer management services. Education & Health Tech Caution: A study found AI helped homework scores but was linked to worse exam results later, especially for students who “outsourced” work. Wellness Science: A Finnish study suggests sauna benefits depend on humidity as much as temperature, supporting the traditional löyly practice. TCM Youth Engagement: Beijing Tong Ren Tang promoted its Hong Kong Student Ambassador Programme for Chinese medicine and health care. Healthcare Business in HK: Axiom Biosciences said it plans an IPO on HKEX in 2027, aiming to raise up to $200m to advance regenerative therapies for newborn brain injuries.